Mural Oncology (MURA)
NASDAQ: MURA
· Real-Time Price · USD
1.77
0.00 (0.00%)
At close: Aug 15, 2025, 3:59 PM
1.79
1.13%
After-hours: Aug 15, 2025, 05:02 PM EDT
Mural Oncology Income Statement
Financials in USD. Fiscal
year is
undefined.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 |
Revenue | 3.49M | 3.49M | 3.49M | 2.62M | 2.62M | 2.62M | 2.62M | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 868K | 1.77M | 2.61M | 2.36M | 3.14M | 2.24M | 1.92M | 1.81M | 1.4M | 1.4M | 869K | 372K |
Gross Profit | 1.75M | 846K | n/a | 259K | -520K | 380K | 696K | -1.81M | -1.4M | -1.4M | -869K | -372K |
Operating Income | -135.69M | -138.61M | -138.26M | -160.92M | -173.13M | -188.26M | -198.38M | -197.46M | -200.45M | -151.04M | -106.89M | -49.3M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -147.15M | -130.73M | -128.51M | -151.8M | -166.35M | -184.19M | -197.43M | -197.46M | -200.45M | -151.04M | -106.89M | -49.3M |
Net Income | -147.15M | -130.73M | -128.51M | -153.78M | -173.3M | -194.04M | -209.59M | -208.86M | -208.22M | -155.92M | -109.45M | -50.64M |
Selling & General & Admin | 29.28M | 27.94M | 27.6M | 36.13M | 35.58M | 35.55M | 32.55M | 28.59M | 27.16M | 20.46M | 16.84M | 4.53M |
Research & Development | 107.66M | 111.52M | 110.67M | 123.54M | 136.31M | 151.86M | 165.31M | 168.34M | 172.75M | 130.06M | 90.05M | 44.77M |
Other Expenses | 17.49M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 152.31M | 137.75M | 136.55M | 160.07M | 172.29M | 187.41M | 197.85M | 196.93M | 199.92M | 150.51M | 106.89M | 49.3M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | -546K | -546K | -546K | -546K | -130K | -130K | -130K | -130K | n/a | n/a |
Cost & Expenses | 104.34M | 138.61M | 138.26M | 160.92M | 173.13M | 188.26M | 198.38M | 197.46M | 200.45M | 151.04M | 106.89M | 49.3M |
Income Tax Expense | n/a | n/a | n/a | 1.98M | 6.94M | 9.85M | 12.16M | 11.4M | 7.78M | 4.87M | 2.56M | 1.34M |
Shares Outstanding (Basic) | 17.27M | 17.17M | 17.07M | 17.03M | 16.92M | 16.79M | 16.69M | 16.69M | 16.69M | 16.69M | 16.69M | 16.69M |
Shares Outstanding (Diluted) | 17.27M | 17.17M | 17.07M | 17.03M | 16.92M | 16.79M | 16.69M | 16.69M | 16.69M | 16.69M | 16.69M | 16.69M |
EPS (Basic) | -8.59 | -7.67 | -7.58 | -9.14 | -10.34 | -11.61 | -12.55 | -12.5 | -12.46 | -9.33 | -6.55 | -3.03 |
EPS (Diluted) | -8.59 | -7.67 | -7.58 | -9.14 | -10.34 | -11.61 | -12.55 | -12.5 | -12.46 | -9.33 | -6.55 | -3.03 |
EBITDA | -101.72M | -135.1M | -134.75M | -156.71M | -169.05M | -182.28M | -192.72M | -192.86M | -196.26M | -149.65M | -106.02M | -48.93M |
EBIT | -104.34M | -135.9M | -135.55M | -158.21M | -170.42M | -186.12M | -196.24M | -195.31M | -198.3M | -151.04M | -106.89M | -49.3M |
Depreciation & Amortization | 2.62M | 3.52M | 3.51M | 3.26M | 3.14M | 2.88M | 2.57M | 2.45M | 2.04M | 1.4M | 869K | 372K |